Features of massive hepatocellular carcinomas

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 1, 2014, Pages 101-108

  Carr, Brian I ^a,b   Guerra, Vito ^b  

^a Department of HCC Biology ^*  (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

fetoprotein; glutamyl transpeptidase; Alkaline phosphatase; Hepatocellular carcinoma; Size; Survival

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASSIVE HEPATOCELLULAR CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; TUMOR VOLUME;

ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84889239586     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283644c49     Document Type: Article

References (41)

1. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270-285.
2. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221-228.
3. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, et al. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2012 [Epub ahead of print].
4. Adam R, Bhangui P, Vibert E, Azoulay D, Pelletier G, Duclos-Vallée JC, et al. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg 2012; 256:883-891.
5. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinic-histopathologic study of 804 North American patients. Am J Clin Path 1996; 105:65-75.
6. Okuda K, Nakashima T, Kojiro M, Kondo Y, Wada K. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989; 97:140-146. (Pubitemid 19191008)
7. Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995; 75:2220-2232.
8. Truant S, Boleslawsky E, Duhamel A, Bouras AF, Louvet A, Febvay C, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol 2012 [Epub ahead of print].
9. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107:2212-2222.
10. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 2010; 82:539-545.
11. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138-148.
12. Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 2012; 83:339-345.
13. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology 2012; 83:331-338.
14. Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wissensch Med 1872; 39:237-249.
15. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114:497-500.
16. Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10:2472-2477.
17. Carr BI, Guerra B. Thrombocytosis and HCC. Dig Dis Sci 2013; 58: 1790-1796.
18. Schwartz ME, Shrager B. Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience. Recent Results Cancer Res 2013; 190:85-100.
19. Tsoulfas G, Mekras A, Agorastou P, Kiskinis D. Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg 2012; 82:510-517.
20. Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, et al. Prognosis and results after resection of very large (>or = 10 cm) hepatocellular carcinoma. J Gastrointest Surg 2007; 11:589-595.
21. Liau KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR, et al. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer 2005; 104:1948-1955. (Pubitemid 41513179)
22. Capussotti L, Muratore A, Amisano M, Massucco P, Polastri R, Bouzari H. Liver resection for large size hepatocellular carcinomas in 47 non-cirrhotic patients-no mortality and long survival. Hepatogastroenterology 2006; 53:768-772. (Pubitemid 44682999)
23. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009; 249:118-123.
24. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 2007; 14:2817-2823. (Pubitemid 47460658)
25. Lee NH, Chau GY, Lui WY, King KL, Tsay SH, Wu CW. Surgical treatment and outcome in patients with hepatocellular carcinoma greater than 10 cm diameter. Br J Surg 1998; 85:1654-1657. (Pubitemid 28548341)
26. Yu MC, Chan KM, Lee CF, Lee YS, Eldeen FZ, Chou HS, et al. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg 2011; 15:1440-1449.
27. Yeh CN, Chen MF, Lee WC, Jeng LB. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol 2002; 81:195-202.
28. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290-2300.
29. Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detect Prev 2007; 31:154-160. (Pubitemid 46669814)
30. Hultcrantz R, Eriksson LC. The source of serum alkaline phosphatases in liver-tumour-bearing rats. Liver 1989; 9:216-222. (Pubitemid 19206849)
31. Maeda M, Koyama W, Sato C, Marumo F, Kanayama M, Uchida T. Hepatocellular carcinoma producing universal type of alkaline phosphatase. Dig Dis Sci 1993; 38:757-761. (Pubitemid 23121287)
32. Evarts RP, Nakatsukasa H, Marsden ER, Hsia CC, Dunsford HA, Thorgeirsson SS. Cellular and molecular changes in the early stages of chemical hepatocarcinogenesis in the rat. Cancer Res 1990; 50: 3439-3444. (Pubitemid 20190157)
33. Ishii H, Okuno F, Shigeta Y, Yasuraoka S, Ebihara Y, Takagi T, Tsuchiya M. Significance of serum gamma glutamyl transpeptidase as a marker of alcoholism. Pharmacol Biochem Behav 1980; 13 (Suppl 1):95-99.
34. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19:314-318. (Pubitemid 38338741)
35. Maass T, Thieringer FR, Mann A, Longerich T, Schirmacher P, Strand D, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer 2011; 128:1259-1268.
36. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012; 12:56.
37. Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, Clavien PA. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010; 51:1244-1254.
38. Zhou J, Tang YZ, Fan J, Wu ZQ, Li XM, Liu YK, et al. Expression of plateletderived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 2000; 126:57-61. (Pubitemid 30006353)
39. Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol 2010; 25:1543-1549.
40. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52:280-281.
41. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136:1012-1024.